OasisLMS

In this episode of Lung Cancer Considered, Drs. Jacob Sands, Ferdinandos Skoulidis, and Jarushka Naidoo discuss key research highlights from ESMO 2026, including results from the DeLLphi-305 trial evaluating tarlatamab in extensive-stage small cell lung cancer and the KRAScendo-1 trial investigating divarasib in KRAS G12C-mutated NSCLC. The discussion also explores emerging immunotherapy strategies, including findings from the MOIO and OptiTROP-Lung06 studies, advances in predicting immune-related toxicities, and the potential implications of these developments for clinical practice.